Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC001 plus paclitaxel versus placebo plus paclitaxel in previously treated advanced gastric or gastroesophageal junction adenocarcinoma
CTR20231207Phase 3Active
- Sponsor
- Shandong Buchang Shenzhou Pharmaceutical
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of BC001 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Shandong Buchang Shenzhou Pharmaceutical. Started Aug 2023; status: active.
02
Drugs
BC001
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20231207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231207.